Procept Biorobotics

Procept Biorobotics Current Assets

The Current Assets of Procept Biorobotics (PRCT) as of Oct 10, 2026 is 450.38 M USD. In the previous year, Current Assets was 481.84 M USD — a change of -6.53% (lower).

Current Assets

450.38 MUSD

YoY

-6.53%

Last updated:

Current Assets of Procept Biorobotics is 2025 450.38 M USD. Current Assets of Procept Biorobotics was 2024 481.84 M USD. It decreases by -6.53% lower compared to the previous year.

The Procept Biorobotics Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2019
50.36 M USD
Jan 1, 2020
109.85 M USD
Jan 1, 2021
325.38 M USD
Jan 1, 2022
272.65 M USD
Jan 1, 2023
350.57 M USD
Jan 1, 2024
481.84 M USD
Jan 1, 2025
450.38 M USD
The Procept Biorobotics Current Assets history
YEARCurrent AssetsYoY
450.38 MUSD-6.53%
481.84 MUSD+37.45%
350.57 MUSD+28.58%
272.65 MUSD-16.20%
325.38 MUSD+196.20%
109.85 MUSD+118.14%
50.36 MUSD—
Access this data via the Eulerpool API

Procept Biorobotics Stock analysis

What does Procept Biorobotics do? PROCEPT BioRobotics Corp (PROCEPT) is a California-based medical technology company specializing in the development of robotic technologies for urological surgery. History: PROCEPT was founded in 2013 by Dr. Chin and his group at Johns Hopkins University School of Medicine. They developed a novel technology that had the potential to revolutionize the treatment of prostate cancer. PROCEPT used a robust Intuitive Surgical platform and developed a novel tissue classification technology that allows surgeons to operate with accuracy and safety. The first system, called AquaBeam®, was approved by the US Food and Drug Administration (FDA) in 2018 and has since been in use in Europe and the US. Business: PROCEPT aims to improve urological surgery through the use of robotic technologies, thereby increasing patient safety and care. The company focuses on the development and commercialization of robotic systems for the treatment of prostate cancer and other urological diseases. Products: PROCEPT has developed Aquablation®, a robotic system for the treatment of prostate cancer. It is a minimally invasive technology that uses high-precision waterjet cutting (accuracy reduced to millimeters) to remove cancerous tissue quickly, effectively, and accurately. The technology can also be used in surgical procedures on the bladder, urethra, and other urological organs. Divisions: PROCEPT has a broad portfolio of services and products in the field of urological surgery. The AquaBeam® technology is the first system developed to treat malignant prostate tumors using robotic technologies. The technology is used in hospitals, clinics, and medical facilities worldwide. In addition, PROCEPT offers training and support for surgeons and medical personnel. Conclusion: PROCEPT BioRobotics Corp is an emerging medical technology company specializing in robotics-based urological surgery. The AquaBeam® technology is an innovative, robotic technology for the treatment of prostate cancer. The company is on its way to revolutionizing urological surgery and making a significant contribution to improving healthcare. Procept Biorobotics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Procept Biorobotics stock

Current Assets of Procept Biorobotics is 450.38 M USD in 2025.

Current Assets of Procept Biorobotics changed from 481.84 M USD to 450.38 M USD, representing a -6.53% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets Procept Biorobotics since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Procept Biorobotics historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Procept Biorobotics

All Key Metrics — Procept Biorobotics